← Back to Search

T1 Colorectal Cancer, Without Recurrence (Training) for Colorectal Cancer (T1CR Trial)

N/A
Recruiting
Led By Ajay Goel, PhD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights

T1CR Trial Summary

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

Eligible Conditions
  • Colorectal Cancer

T1CR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence-free Survival

T1CR Trial Design

4Treatment groups
Experimental Treatment
Group I: T1 Colorectal Cancer, Without Recurrence (Validation)Experimental Treatment1 Intervention
Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort
Group II: T1 Colorectal Cancer, Without Recurrence (Training)Experimental Treatment1 Intervention
Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort
Group III: T1 Colorectal Cancer, With Recurrence (Validation)Experimental Treatment1 Intervention
Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort
Group IV: T1 Colorectal Cancer, With Recurrence (Training)Experimental Treatment1 Intervention
Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,260 Total Patients Enrolled
Ajay Goel, PhDPrincipal InvestigatorCity of Hope Medical Center
6 Previous Clinical Trials
4,177 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
2023. "Predicting Local and Distant Recurrence in T1 Colorectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06314971.
All > Anaheim > Paid Studies Ventura
~83 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top